Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Want to see KPTI full AI Analyst Report?
KPTI Stock Chart & Stats
$8.61
-$0.04(-5.28%)
At close: 4:00 PM EST
$8.61
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.65 - $10.99
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$206.46M
Enterprise Value$217.80M
Total Cash (Recent Filing)$90.85M
Total Debt (Recent Filing)$230.87M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Jul 30, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.84
Shares Outstanding22,662,943
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.50
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$15.83Price Target Upside83.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.31
Revenue Forecast (FY)$137.49M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption PotentialHigh overlap between the targeted myelofibrosis patient population and existing community accounts, combined with strong physician intent to adopt the combination therapy, suggests potential for rapid commercial uptake upon approval.
Financial RunwayRecent equity financing and a credit agreement amendment provide additional cash and payment flexibility, which reduces near-term funding pressure and extends the operational runway toward key trial readouts.
Overall Survival SignalObserved early overall survival benefit could bolster regulatory and investor confidence if supported by follow-up analyses, increasing upside potential for the program.
Bears Say
Binary Trial Outcome RiskThe requirement to meet both spleen volume reduction and symptom improvement as co-primary endpoints makes the trial outcome binary and increases the likelihood of a negative regulatory decision if either endpoint is missed.
Franchise Performance And Dilution RiskUnderperformance in the existing multiple myeloma franchise and the possibility of future financing raise dilution concerns and may keep the stock valuation constrained until clearer clinical or commercial progress emerges.
Symptom Endpoint Failure RiskSENTRY's lack of improvement on symptom scores despite spleen benefit weakens the case for approval and could limit the product's labeling or market access.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.65 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $206.46M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 61 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on May 14, 2026. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.417 by $0.177.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -1.31.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,662,943 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.417. Following the earnings report the stock price went up 0.565%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.83 (83.89% Upside)
$15.83 (83.89% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 20.2%
Last 30 Days ▲ 20.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
77.87%
Trailing 12-Months
Asset Growth
-28.56%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong clinical momentum and significant near-term catalysts: compelling Phase III SENTRY results with a statistically robust spleen response and an intriguing overall survival signal, completed enrollment in EC042 with prior SIENDO data showing deep and durable PFS benefit, ASCO presentation and planned mid-2026 manuscript, and quarter-over-quarter revenue improvement driven by gross-to-net gains. These positives are tempered by competitive pressure that reduced underlying demand for XPOVIO, gross-to-net volatility, continued net losses and high operating spend, and a limited cash runway into late Q3 2026 that may necessitate additional financing or milestone events. Regulatory timing and the need for further data granularity (e.g., deaths attribution) add some near-term uncertainty. On balance, the clinical and strategic highlights are material and potentially value-creating, though execution and financing risks remain.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$15.83
▲(83.89% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
3.66% Insiders
18.47% Mutual Funds
73.51% Other Institutional Investors
0.88% Public Companies and
Individual Investors